Viewing data from:

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

ANDA

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE | A202912 | LUPIN LTD

1 strength0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
ViiV Healthcare UK Ltd. et al v. Lupin Ltd. et al 1:2011cv00576 1 patentANDA 202912zidovudine, abacavir, lamivudine	D. Del.	2011-06-29	Terminated 2014-01-24	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Dec 9, 2013	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 300MG BASE;150MG;300MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Dec 5, 2013

No patent or exclusivity listings for this strength.